Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

Retatrutide + MOTS-c Stack: Evidence Map (Not a Protocol)

By SaiyanMed Research Team · Updated 4 November 2026 · For in-vitro / laboratory research use only

Quick answer

Online “stack” pages often pair retatrutide (LY3437943), a unimolecular agonist of the GIP, GLP-1 and glucagon receptors,[1][2] with MOTS-c, a 16-amino-acid peptide encoded in mitochondrial 12S rRNA that has been linked in peer-reviewed work to AMPK-related metabolic signalling and mito–nuclear communication.[3][4] Complementary-mechanism storytelling is not the same thing as co-administration evidence. As of 4 November 2026, a PubMed Title/Abstract search for (retatrutide OR LY3437943) AND (MOTS-c OR "MOTS c") returned zero records, and no ClinicalTrials.gov intervention was identified that combines both agents. This page is an evidence map and laboratory-identity primer for researchers reading grey-market claims — not a reconstitution guide, not an injection or dose schedule, and not medical advice.

Key takeaways

  • Combination evidence grade: none. No peer-reviewed human or animal co-administration study of retatrutide + native MOTS-c was found on the search date above.
  • Different biological hypotheses. Retatrutide is engineered incretin/glucagon polypharmacology;[1] MOTS-c is a mitochondrial-derived peptide (MDP) studied for metabolic homeostasis and stress-responsive nuclear gene regulation.[3][4] “Complementary” in a blog outline ≠ demonstrated synergy.
  • CB4211 ≠ MOTS-c. The completed Phase 1 programme NCT03998514 evaluates CB4211, a CohBar clinical candidate described as a MOTS-c analogue — not native MOTS-c sequence identity as a retatrutide stack partner.[5]
  • Near-miss papers are easy to misuse. In-vitro pancreatic effects of MOTS-c (Bień et al.) and circulating MOTS-c changes under GLP-1RA ± SGLT2i therapy (Ikonomidis et al.) do not establish an exogenous retatrutide + MOTS-c regimen.[6][7]
  • Human MOTS-c literature is mostly endogenous / exercise / observational. Reynolds et al. (2021) frame MOTS-c in exercise and aging biology — not co-dosing with a triple agonist.[8]
  • RUO / identity first. Match LY code, CAS, sequence and MS/HPLC on any research COA before discussing mechanisms. See how to read a peptide COA.

Contents

  1. Identity cards
  2. Why grey-market “stack” discourse exists
  3. Mechanism map (separate pillars)
  4. Evidence grade for the combination
  5. Near-miss papers people cite incorrectly
  6. Myth vs evidence
  7. Laboratory verification, COA, and doping-context literacy
  8. Decision tree for researchers reading the literature
  9. Glossary
  10. FAQ
  11. Research Use Only Disclaimer
  12. References

Identity cards

Property Retatrutide MOTS-c (native) Source
Common name Retatrutide MOTS-c (mitochondrial ORF of the 12S rRNA type-c) [2][3]
Developer / discovery code LY3437943 (Eli Lilly) Endogenous MDP; synthetic research material is chemically manufactured [1][3]
CAS (commonly cited) 2381089-83-2 1627580-64-6 Registry / PubChem practice[9]
Sequence / class Engineered multi-receptor peptide agonist 16 aa: MRWQEMGYIFYPRKLR [3][9]
PubChem (MOTS-c) — CID 146675088 (MF C101H152N28O22S2; MW ≈ 2174.6) [9]
Primary pharmacology framing GIPR + GLP-1R + GCGR (unimolecular); discovery abstract: balanced GCGR & GLP-1R activity with relatively more GIPR activity Folate-cycle / de novo purine-linked AMPK activation; nuclear translocation under metabolic stress [1][3][4]
Lead human evidence (agent alone) Phase 2 obesity (NEJM); Phase 3 TRIUMPH-1 (NEJM) Mostly endogenous/exercise/observational human biology; exogenous clinical MOTS-c ≠ CB4211 [2][10][8][5]
Same molecule as CB4211? N/A No — CB4211 is a separate clinical analogue programme [5]
Co-administration evidence with the other column None identified (PubMed 0; no combo registry arm found, 4 Nov 2026) This search

Research-supply pages for identity context (not treatment claims): Retatrutide peptide (LY3437943) · MOTS-c (human) peptide. Primers: What is MOTS-c? · SS-31 vs MOTS-c · Eloralintide vs retatrutide (different receptor-system comparison for retatrutide neighbours).

Why grey-market “stack” discourse exists

Three content incentives collide:

  1. High-attention retatrutide narrative. Peer-reviewed Phase 2 and Phase 3 obesity datasets make LY3437943 a durable search magnet.[2][10]
  2. Mitochondrial “metabolic switch” narrative. Lee (2015), Kim (2018) and Reynolds (2021) give MOTS-c a scientifically real, citation-rich story about AMPK, nuclear gene regulation and exercise biology — easy for non-peer-reviewed sites to paste next to any incretin page.[3][4][8]
  3. Stack-directory SEO. Catalogue sites list dozens of named combinations (market surveys in 2026 document Peptigraph-, Claritide-, Pepflow- and dosing-protocol-style hubs). A dedicated URL such as a “retatrutide + MOTS-c dosage & schedule” page can rank for commercial intent without owning a single combo RCT.

Those incentives explain why the pages exist. They do not upgrade the combination’s evidence grade.

Mechanism map (separate pillars)

Pillar A — Retatrutide (LY3437943)

Coskun et al. (Cell Metabolism, 2022) describe LY3437943 as a novel triple agonist at GCGR, GIPR and GLP-1R. The abstract states that in vitro the peptide shows balanced GCGR and GLP-1R activity but more GIPR activity; that in obese mice weight loss was augmented by GCGR-linked energy-expenditure increases added to GIPR- and GLP-1R-linked intake reduction; and that Phase 1 pharmacokinetics supported once-weekly dosing.[1] Exact numeric EC50 tables from the full PDF are not re-verified end-to-end in this draft (publisher gate); treat secondary “X-fold vs native ligand” charts with caution unless you open the paper yourself.

Clinical literacy (agent alone, not a stack): Jastreboff et al. Phase 2 (NEJM, 2023; NCT04881760) and TRIUMPH-1 Phase 3 (NEJM, 2026; NCT05929066) report placebo-controlled obesity programmes with published percent weight-change series and gastrointestinal adverse-event patterns.[2][10][11][12] Those results describe retatrutide monotherapy trials. They are not MOTS-c combination results and must not be arithmetically “added” to MOTS-c animal percentages.

Pillar B — MOTS-c

Lee et al. (Cell Metabolism, 2015) identified MOTS-c as a 16-amino-acid peptide encoded by a short ORF in mitochondrial 12S rRNA. The paper links cellular actions to inhibition of the folate cycle and tethered de novo purine biosynthesis with downstream AMPK activation, and reports mouse experiments in which MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity under the study conditions. Skeletal muscle is framed as a primary target organ.[3]

Kim et al. (Cell Metabolism, 2018; PMID 29983246) show that MOTS-c can translocate to the nucleus under metabolic stress in an AMPK-dependent manner and regulate nuclear genes including antioxidant-response-element programmes, with interaction involving factors such as NFE2L2/NRF2.[4]

Reynolds et al. (Nature Communications, 2021) extend the human and mouse story toward exercise-inducible MOTS-c biology and physical-capacity / aging frames.[8] That is endogenous physiology and exercise science — a different question from purchasing two research vials and declaring a “stack.”

Why blogs call them “complementary”

A typical non-peer-reviewed outline claims: retatrutide covers systemic energy intake / expenditure polypharmacology; MOTS-c “covers” muscle metabolic flexibility / mitochondrial signalling. As a hypothesis generator for separate experiments, that sentence is coherent. As a claim that co-administration is evidence-based, it fails the combination evidence test below.

Evidence grade for the combination

Question Finding (as of 4 Nov 2026) Grade
PubMed hits for retatrutide/LY3437943 ∩ MOTS-c 0 Title/Abstract records None
Registered human trial of retatrutide + MOTS-c None identified None
Registered animal study of the same pair None identified in the same search pass None
Retatrutide monotherapy human obesity evidence Phase 2 + Phase 3 peer-reviewed Mature for reta alone
Native MOTS-c exogenous human interventional efficacy for obesity Not established as a labelled, peer-reviewed Phase 2/3 programme equivalent to retatrutide Weak / indirect
CB4211 Phase 1 (analogue) NCT03998514 completed (safety/PK/PD in healthy and NAFLD cohorts) Early analogue data ≠ native MOTS-c stack

Reading rule: ingredient-level evidence does not transitively become combination evidence. The same rule applies in the opposite direction: absence of a combo RCT does not “disprove” every future hypothesis — it only means current stack marketing overclaims the literature.

Near-miss papers people cite incorrectly

1) Bień et al., 2024 — pancreatic α/β cell physiology in vitro

PMID 38430258 reports that MOTS-c influences pancreatic cell-line physiology (INS-1E and αTC-1), including effects relevant to insulin/glucagon-axis readouts under the assay conditions.[6] Correct use: a cell-biology caveat if someone is designing experiments near glucagon receptor biology. Incorrect use: claiming proven systemic synergy between a GCGR-containing triple agonist and MOTS-c in humans.

2) Ikonomidis et al., 2025 — circulating MOTS-c under GLP-1RA ± SGLT2i

PMID 40008510 measures biomarkers including MOTS-c in people with type 2 diabetes treated with insulin, liraglutide, empagliflozin, or GLP-1RA+SGLT2i combination.[7] Correct use: endogenous MOTS-c as a circulating analyte under approved-drug classes. Incorrect use: equating liraglutide/empagliflozin biomarker shifts with (a) retatrutide pharmacology or (b) intentional exogenous MOTS-c administration alongside retatrutide.

3) CB4211 / NCT03998514 — analogue Phase 1

NCT03998514 is a completed Phase 1a/1b randomised, double-blind, placebo-controlled study of CB4211 safety, tolerability, PK and PD after single and multiple ascending subcutaneous doses in healthy non-obese participants and participants with NAFLD.[5] Label the molecule correctly: CB4211 ≠ native MOTS-c, and Phase 1 ≠ obesity Phase 3.

Myth vs evidence

Claim circulating in stack SEO What the literature actually supports
“Retatrutide + MOTS-c is a researched synergy stack.” No PubMed combo hit; no identified co-administration trial (4 Nov 2026).
“MOTS-c clinical data prove the stack.” Often CB4211 Phase 1 or endogenous/exercise papers are quietly substituted.
“Add the weight-loss % from reta trials to MOTS-c mouse %.” Invalid arithmetic across species, designs and estimands.
“GLP-1 drugs raise MOTS-c, so stacking is science-backed.” Ikonomidis-style biomarker work ≠ exogenous MOTS-c + retatrutide RCT.[7]
“Glucagon receptor activity means MOTS-c must synergise.” In-vitro islet findings are not systemic combo proof.[6]
“If doping labs detect MOTS-c, it must be an effective performance drug.” Detection methods exist for sports drug testing; analytical capability ≠ approved efficacy.[13]

Laboratory verification, COA, and doping-context literacy

For research procurement and notebook integrity:

  • Retatrutide: confirm LY3437943 naming on the COA; reconcile CAS 2381089-83-2 with supplier documentation; require HPLC purity and mass identity consistent with the labelled peptide.
  • MOTS-c: confirm the 16-aa sequence MRWQEMGYIFYPRKLR (or explicitly labelled analogue — do not silently accept “MOTS-c” as CB4211); CAS 1627580-64-6 / PubChem CID 146675088 as cross-checks;[9] HPLC + MS.
  • Do not assume vial labels imply clinical grade. Research-use materials are not substitutes for authorised medicinal products.
  • Doping-control context: Knoop et al. developed LC/MS detection of MOTS-c in plasma for sports drug testing and discussed endogenous reference considerations.[13] That literature is relevant to identity / forensics awareness for laboratories — it is not a clinical efficacy dossier and is not a protocol.

Practical COA literacy: How to read a peptide COA.

Decision tree for researchers reading the literature

Use this when a blog, vendor page or forum asserts a “reta + MOTS-c stack.” This is a literature triage for laboratory researchers — not a patient care pathway.

  1. Is the claim about endogenous MOTS-c (exercise, aging, circulating levels)? → Read Reynolds / observational clinical biomarker papers on their own terms. Stop calling it a vial stack.
  2. Is the clinical citation actually CB4211? → Open NCT03998514; relabel the molecule; do not transfer Phase 1 analogue PK to native MOTS-c + retatrutide.
  3. Does the citation list contain any paper with both retatrutide/LY3437943 and MOTS-c in the same study? → As of 4 Nov 2026, expect “no.” If someone claims yes, demand PMID/NCT and read methods.
  4. Is a retatrutide % weight-change table being shown next to MOTS-c mouse data? → Treat as scoreboard SEO. Keep columns in separate notebooks.
  5. Are you designing a new controlled experiment? → Pre-register hypotheses; justify each agent separately; do not copy grey-market schedules; follow institutional IACUC/IRB and RUO supplier constraints.
  6. Are you only verifying material identity? → Sequence/LY/CAS + HPLC/MS + COA trail is sufficient; mechanism blogs are optional colour, not certificates.

Glossary

AMPK
AMP-activated protein kinase — cellular energy sensor; MOTS-c papers link folate/purine pathway effects to AMPK activation.[3]
CB4211
CohBar clinical analogue candidate studied in NCT03998514; not native MOTS-c.
Combination evidence grade
Quality of evidence for co-administration, distinct from evidence for each ingredient alone.
GCGR / GIPR / GLP-1R
Glucagon, GIP and GLP-1 receptors — the three targets named for retatrutide.
MDP
Mitochondrial-derived peptide — peptides encoded by mtDNA short ORFs (e.g., MOTS-c, humanin family).
RUO
Research Use Only — laboratory supply context; not for human or veterinary administration as therapy.

FAQ

Is there clinical evidence for taking retatrutide and MOTS-c together?

No peer-reviewed co-administration study of retatrutide (LY3437943) with native MOTS-c was identified as of 4 November 2026 (PubMed Title/Abstract count 0; no matching combo registry arm found). Monotherapy retatrutide trials do not answer the combination question.

Why do so many websites recommend the stack anyway?

Because complementary-mechanism storytelling + high search demand for retatrutide creates SEO inventory. Catalogue and dosing-farm sites can publish a URL without owning combo RCTs. Mechanism adjacency is not synergy proof.

Does CB4211 Phase 1 count as MOTS-c clinical proof for this stack?

No. NCT03998514 evaluates CB4211, described as a MOTS-c analogue programme, for safety/PK/PD in healthy and NAFLD cohorts.[5] It is not a retatrutide combination trial and is not native MOTS-c sequence identity by default.

What human evidence exists for MOTS-c itself?

Much of the strongest peer-reviewed human framing is endogenous biology (e.g., exercise-inducible MOTS-c in Reynolds et al., 2021).[8] Do not equate that literature with an authorised obesity drug programme comparable to retatrutide’s Phase 2/3 dataset.

MOTS-c affects glucagon in cell studies — doesn’t that prove synergy with retatrutide?

It proves you should read Bień et al. carefully if your in vitro system involves α/β cells.[6] It does not prove safe or effective systemic co-administration with a GCGR-containing agonist in humans.

What dose / reconstitution should researchers use?

This page intentionally provides none. Grey-market schedule pages are not a substitute for institutional protocols, validated methods, or (where applicable) authorised product labelling. SaiyanMed content here is evidence literacy and identity verification only.

Where do the product links fit?

Links to retatrutide and MOTS-c (human) are for research-material identity and procurement context on a RUO catalogue — not prescriptions, not clinic protocols, and not efficacy claims for a combined regimen.

{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “Is there clinical evidence for taking retatrutide and MOTS-c together?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No peer-reviewed co-administration study of retatrutide (LY3437943) with native MOTS-c was identified as of 4 November 2026 (PubMed Title/Abstract count 0; no matching combo registry arm found). Monotherapy retatrutide trials do not answer the combination question.”
}
},
{
“@type”: “Question”,
“name”: “Why do so many websites recommend the retatrutide + MOTS-c stack?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Complementary-mechanism storytelling plus high search demand for retatrutide creates SEO inventory. Catalogue and dosing-farm sites can publish a URL without owning combination RCTs. Mechanism adjacency is not synergy proof.”
}
},
{
“@type”: “Question”,
“name”: “Does CB4211 Phase 1 count as MOTS-c clinical proof for a retatrutide stack?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “No. NCT03998514 evaluates CB4211, a MOTS-c analogue programme, for safety, pharmacokinetics and pharmacodynamics in healthy and NAFLD cohorts. It is not a retatrutide combination trial and is not native MOTS-c by default.”
}
},
{
“@type”: “Question”,
“name”: “What human evidence exists for MOTS-c itself?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Much of the strongest peer-reviewed human framing is endogenous biology, such as exercise-inducible MOTS-c discussed by Reynolds et al. (2021). That literature should not be equated with an authorised obesity drug programme comparable to retatrutide Phase 2/3 datasets.”
}
},
{
“@type”: “Question”,
“name”: “MOTS-c affects glucagon in cell studies — does that prove synergy with retatrutide?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “In-vitro pancreatic findings (e.g., Bień et al., 2024) are experimental caveats for cell systems involving alpha and beta cells. They do not prove safe or effective systemic co-administration with a glucagon-receptor-containing agonist in humans.”
}
},
{
“@type”: “Question”,
“name”: “What dose or reconstitution should be used for a retatrutide + MOTS-c stack?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “This educational page intentionally provides no dose, injection, or reconstitution schedule. Grey-market protocol pages are not substitutes for institutional methods or authorised labelling. Content here is limited to evidence literacy and laboratory identity verification for research use only.”
}
},
{
“@type”: “Question”,
“name”: “How do SaiyanMed product links relate to this article?”,
“acceptedAnswer”: {
“@type”: “Answer”,
“text”: “Product links for retatrutide and MOTS-c (human) provide research-material identity and procurement context on a research-use-only catalogue. They are not prescriptions, clinic protocols, or efficacy claims for a combined regimen.”
}
}
]
}

Research Use Only Disclaimer

All SaiyanMed materials referenced from this page are supplied for laboratory research use only. They are not medicines, not dietary supplements for consumer use, and not intended for human or veterinary therapeutic administration. Nothing on this page is medical advice, a dosing protocol, or encouragement to compound or self-administer investigational peptides. Regulatory status of investigational agents (including retatrutide) and of research peptides can change; verify primary sources and applicable law for your jurisdiction.

References

  1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist… Cell Metab. 2022. PMID 35985340. DOI 10.1016/j.cmet.2022.07.013.
  2. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315. DOI 10.1056/NEJMoa2301972.
  3. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis… Cell Metab. 2015. PMID 25738459. DOI 10.1016/j.cmet.2015.02.009.
  4. Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus… Cell Metab. 2018. PMID 29983246. DOI 10.1016/j.cmet.2018.06.008.
  5. ClinicalTrials.gov. NCT03998514 — Phase 1a/1b study of CB4211. https://clinicaltrials.gov/study/NCT03998514.
  6. Bień J, et al. MOTS-c regulates pancreatic alpha and beta cell functions in vitro. 2024. PMID 38430258.
  7. Ikonomidis I, et al. Effects of GLP-1RA, SGLT2i, and their combination on… MOTS-c… 2025. PMID 40008510.
  8. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. PMID 33473109. DOI 10.1038/s41467-020-20790-0.
  9. PubChem CID 146675088 (MOTS-c). https://pubchem.ncbi.nlm.nih.gov/compound/146675088.
  10. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026. PMID 42814954. DOI 10.1056/NEJMoa2604169.
  11. ClinicalTrials.gov. NCT04881760. https://clinicaltrials.gov/study/NCT04881760.
  12. ClinicalTrials.gov. NCT05929066. https://clinicaltrials.gov/study/NCT05929066.
  13. Knoop A, et al. Development of a mass spectrometry based detection method for… MOTS-c… doping control. Rapid Commun Mass Spectrom. 2019. PMID 30394592.